Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
关于甲磺酸亮丙瑞林注射液（6M）上市申请获得受理的公告
Regulatory Filings Classification · 85% confidence The document is a corporate announcement by Changchun High-Tech regarding the acceptance of a new drug registration application by the National Medical Products Administration. It contains no financial statements or investment metrics, no board or management changes, no dividend or M&A details, and no call transcript or ESG report. It is a regulatory disclosure of business progress (drug approval process), fitting the “Regulatory Filings” fallback category (RNS).
2026-05-29 Chinese
关于子公司GenSci144片境内生产药品注册临床试验申请获得批准的公告
Regulatory Filings Classification · 80% confidence The document is a corporate announcement disclosing that the company’s subsidiary received approval for a domestic drug registration clinical trial from the National Medical Products Administration. It contains no financial statements, earnings data, board changes, or legal proceedings. It is a routine regulatory compliance announcement. This does not fit any specific reporting category (e.g., earnings release, interim report, M&A, etc.) and thus falls into the fallback category of general regulatory announcements.
2026-05-26 Chinese
关于子公司GenSci144片境内生产药品注册临床试验申请获得受理的公告
Regulatory Filings Classification · 91% confidence The document is a public announcement by Changchun High-tech Co., Ltd. about its subsidiary’s clinical trial application acceptance by the national drug regulator. It contains no financial results, no board changes, no dividends, no filings of a formal report (Annual, Interim, Audit), nor detailed supplement data. It is an operational/regulatory update required for compliance. Therefore it fits the “Regulatory Filings” fallback category (RNS).
2026-05-25 Chinese
董事、高级管理人员薪酬管理办法（2026年5月修订）
Remuneration Information Classification · 90% confidence The document is a detailed policy (“办法”) outlining the structure, principles, components, calculation methods, and oversight of remuneration for the company’s board members and senior management. It does not present financial results, voting outcomes, or report publication notices, nor is it a regulatory certification or earnings release. Instead, it specifically details executive and director compensation governance, matching the definition of Remuneration Information (Code: DEF 14A).
2026-05-12 Chinese
关于参加2026年吉林辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 80% confidence The document is a short announcement by the company’s board regarding its participation in an upcoming online investor reception day. It does not contain financial statements, voting results, a proxy statement, or detailed investor presentation content, nor does it announce publication of a report. It is a general regulatory/IR announcement, fitting the fallback category for miscellaneous regulatory filings.
2026-05-12 Chinese
北京大成（长春）律师事务所关于长春高新技术产业（集团）股份有限公司2025年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter issued by Beijing Dacheng (Changchun) law firm regarding the legality of the 2025 annual shareholders’ meeting procedures, attendee qualifications, voting processes, and results. It is not the actual AGM presentation materials (AGM-R), proxy solicitation (PSI), or a straightforward voting results announcement (DVA) but a compliance/legal opinion required under securities law, making it a general regulatory disclosure. It does not contain substantive financial statements or serve as an annual or interim report. Therefore, it falls under the catch-all Regulatory Filings category (RNS).
2026-05-12 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.